Avila Therapeutics is a venture-backed company focused on discovering and developing novel small molecule therapeutics for cancer and viral diseases. Their proprietary Avilomics platform enables the development of covalent drugs that target disease-causing proteins, offering highly effective therapies. They have a strategic alliance with Sanofi-Aventis and offer AVL-181, a small molecule hepatitis C virus protease inhibitor. Avila Therapeutics was incorporated in 2006 and is based in Waltham, Massachusetts, operating as a subsidiary of Celgene Corporation since March 2012.